The announcement of G1 Therapeutics ending the year with a substantial amount of cash and securities, along with a projected cash runway extending into 2025, is likely to instill confidence in investors regarding the company's financial health and stability. This positive financial outlook could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.